UCM-1306

UCM-1306 is an orally bioavailable, small molecule **positive allosteric modulator (PAM)** of the **human dopamine D1 receptor**. It acts by increasing the maximal effect of endogenous dopamine on the D1 receptor in a dose-dependent manner, is inactive in the absence of dopamine, and displays selectivity for the D1 receptor with low orthosteric ligand competition. In preclinical models, UCM-1306 potentiates cocaine-induced locomotion and enhances l-DOPA recovery of decreased locomotor activity, showing promise for the treatment of **Parkinson's disease**, particularly in addressing issues with current D1 agonists and l-DOPA tolerance. The compound is notable for oral activity, lack of receptor desensitization, and a favorable pharmacokinetic and safety profile in animal studies. It was developed by medicinal chemistry efforts at Universidad Complutense de Madrid for neurodegenerative and cognitive indications such as Parkinson's disease[1][2][5][6][7][8].

Other names

2-(fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl